The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer:

Ulrike Nitz,Oleg Gluz,Hans Kreipe,Matthias Christgen,Sherko Kuemmel,Frederick L. Baehner,Steven Shak,Bahriye Aktas,Michael S. Braun,Kerstin Lüdtke-Heckenkamp,Helmut Forstbauer,Eva Maria Grischke,Benno Nuding,Maren Darsow,Claudia Schumacher,Katja Krauss,Wolfram Malter,Marc Thill,Mathias Warm,Rachel Wuerstlein,Ronald E. Kates,Nadia Harbeck

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer:

2020

Background:Endocrine sensitivity, as determined by response of the proliferation marker Ki-67 to short-term preoperative endocrine therapy (ET), is currently not included in adjuvant treatment deci...

Keywords:

Proliferation Marker
Endocrine system
Ki-67
Oncology
Adjuvant
Biomarker (medicine)
Medicine
Breast cancer
Internal medicine
early breast cancer
Preoperative Endocrine Therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations